Background
Unruptured intracranial aneurysms are abnormal bulges in the wall of a brain artery. They are often found by chance during imaging for another reason, and many never rupture. However, when an aneurysm does burst, it can cause subarachnoid hemorrhage, a life-threatening type of bleeding around the brain. Depending on the location and size of the aneurysm, rupture can also be accompanied by bleeding into the brain tissue itself or into the ventricles, worsening outcomes.
Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, are medications widely used for diabetes and, more recently, weight management. Common examples include semaglutide, liraglutide, dulaglutide, and tirzepatide-related incretin therapies, although tirzepatide is a dual GIP/GLP-1 agonist rather than a pure GLP-1RA. These drugs are known not only for lowering blood glucose and supporting weight loss, but also for anti-inflammatory and vascular protective effects. Because inflammation and vessel-wall instability are thought to contribute to aneurysm growth and rupture, researchers have begun to ask whether GLP-1RAs might also help stabilize aneurysms or reduce the severity of a rupture if one occurs.
